A Phase 3 interventional study of ABL001 in Chronic Myelogenous Leukemia - Chronic Phase, sponsored by Novartis Pharmaceuticals. Completed at 26 sites in United States. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2025-10-16.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Leukemia, Myeloid, Chronic-Phase by Novartis — 2 open to participants now, 3 under way, none of them phase 3. Leukemia, Myeloid, Chronic-Phase · Novartis.
Among the 14 studies in Leukemia, Myeloid, Chronic-Phase by Novartis, this one is the only one that started in 2021, is one of 3 in phase 3, and was the 9th registered.
439 studies on the registry are indexed under Leukemia, Myeloid, Chronic-Phase; 27 are open to participants now.
Browse Leukemia, Myeloid, Chronic-Phase studies →2 of the 14 studies in Leukemia, Myeloid, Chronic-Phase by Novartis are open now, in 1 country. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States
Ages 18–100
Novartis Pharmaceuticals
Ages 21–90
By country, each count listing its studies:
Of the 20 Leukemia, Myeloid, Chronic-Phase studies recruiting now, 13 (65%) set no upper age limit and 5 (25%) stop at 75 or younger; 3 take children under 18; 1 takes healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 5 · Phase 3 3 · Phase 4 1
First in 2000; this study’s year is marked. 1 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 56 is above the median of 43 across 322 interventional studies indexed under Leukemia, Myeloid, Chronic-Phase.
Median enrollment 45 across the 6 interventional studies, 700 across the 4 observational. Of the 10 that completed or were terminated, 4 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
1 of the studies in Leukemia, Myeloid, Chronic-Phase by Novartis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07454850Novartis PharmaceuticalsA Study of Patient Characteristics, Co-Morbidities, and Treatment Patterns in Chronic Myeloid Leukemia Patients in Kuwait | 2027-07-02 |
Add it to your calendar (.ics) → With an account.
Among the 14 studies in Leukemia, Myeloid, Chronic-Phase by Novartis, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study was a multicenter Phase IIIb open-label, three-cohort study of asciminib in patients with CML-CP without T315I mutation who have had at least 2 prior TKIs and CML-CP harboring the T315I mutation with at least 1 prior TKI
This trial consisted of three periods: screening and baseline for up to 21 days, active treatment for up to 72 weeks and a safety follow up period for 30 days.
One hundred and fifteen (115) patients with chronic myeloid leukemia in chronic phase (CML-CP) without T315I mutation who have had at least 2 prior Tyrosine Kinase Inhibitors (TKIs) and CML-CP with the T315I mutation with at least 1 prior TKI were planned for this study, however the study was finally completed with 56 participants due to enrollment issues.
Informed consent was obtained before any procedures were performed for the study including eligibility assessments. The results of the real time quantitative polymerase chain reaction (RQ-PCR) must be available prior to randomization and first dose of study treatment.
Patients with CML-CP without T315I mutation were randomly assigned to either cohort A or B. Patients with the T315I mutation were enrolled in cohort C. During treatment period asciminib was taken orally: Cohort A was administered 40 mg twice a day, Cohort B was administered 80 mg once a day and Cohort C was administered 200 mg twice a day. The patients were treated up to end of study treatment period defined as up to 72 weeks after the last patient receives the first dose. Patients may have been discontinued from treatment with the study drug at any time due to unacceptable toxicity, disease progression and/or at the discretion of the investigator or the patient.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants eligible for inclusion in this study must meet all of the following criteria:
Patients must meet all of the following laboratory values at the screening visit:
Prior treatment with a minimum of:
Failure (adapted from the 2020 ELN Recommendations) or intolerance to the most recent TKI therapy at the time of screening
Adequate end organ function, within 12 days before the first dose of asciminib treatment. Patients with mild to moderate renal and hepatic impairment are eligible if:
Treatment with medications that meet one of the following criteria is allowed if used with caution at least one week prior to the start of treatment with study treatment:
Patients must have the following electrolyte values (as per central laboratory tests) within normal limits or corrected to be within normal limits with supplements prior to first dose of study medication:
Exclusion Criteria:
Patients eligible for this study must not meet any of the following criteria:
Cardiac or cardiac repolarization abnormality, including any of the following:
Women of , defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of .
Highly effective contraception methods include:
If a patient is presenting with symptoms suggestive of possible COVID-19 infection, we advise ruling it out by appropriate testing recommended by health authorities.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
40 mg asciminib orally twice daily (BID)
Drug: ABL001
80 mg asciminib orally once daily (QD)
Drug: ABL001
200 mg asciminib orally twice daily (BID)
Drug: ABL001
Asciminib will be supplied as 20 mg or 40 mg strength tablets will be administered orally in accordance with the assigned cohort.
Number of Participants With Adverse Events and Serious Adverse Events for Cohorts A and B up to 24 Weeks
Adverse events (AEs) and serious adverse events (SAEs) are summarized by cohort. Clinically significant findings for vitals, laboratory values and electrocardiogram (ECG) are reported as adverse events and or serious adverse events as determined by the investigator.
Time frame: Baseline to up to 24 Weeks
Number of Participants With Adverse Events and Serious Adverse Events for Cohorts A, B and C by Week 48
Adverse events (AEs) and serious adverse events (SAEs) were summarized by cohort. Clinically significant findings for vitals, laboratory values and electrocardiogram (ECG) were reported as adverse events and or serious adverse events as determined by the investigator.
Time frame: Baseline up to 48 weeks
Number of Participants With Adverse Events and Serious Adverse Events for Cohorts A, B and C by Week 72
Adverse events (AEs) and serious adverse events (SAEs) were summarized by cohort. Clinically significant findings for vitals, laboratory values and electrocardiogram (ECG) were reported as adverse events and or serious adverse events as determined by the investigator.
Time frame: Baseline up to 72 weeks
Percentage of Patients Achieving Complete Hematologic Response (CHR) for Cohorts A, B and C
A complete hematologic response (CHR) is defined as all of the following present for ≥ 4 weeks: * White blood cell count (WBC) \<10 x 10\^9/L * Platelet count \<450 x 10\^9/L * Basophils \<5%, * No blasts and promyelocytes in peripheral blood * Myelocytes + metamyelocytes \< 5% in peripheral blood * No evidence of extramedullary disease, including spleen and liver The estimated cumulative incidence rates were presented.
Time frame: Baseline to 12, 24, 48, 72 weeks
Percentage of Patients Achieving Major Molecular Response (MMR) for Cohorts A, B and C
The rate of major molecular response (MMR) by 12, 24, 48 and 72 weeks after the start of first study medication is defined as ≥ 3 log reduction of BCR-ABL (transcript from standardized baseline or ≤0.1% BCR-ABL/ABL % by international scale, measured by real-time quantitative polymerase chain reaction (RQ-PCR). BCR-ABL fusion gene is also called the Philadelphia chromosome. The estimated cumulative incidence rates were presented.
Time frame: Baseline up to 12, 24, 48, 72 weeks
Percentage of Patients Achieving Molecular Response (MR2) for Cohorts A, B and C
The rate of molecular response (MR2) by 12, 24, 48 and 72 weeks after the start of first study medication is defined as ≥ 2 log reduction of BCR-ABL (transcript from standardized baseline or ≤ 1% BCR-ABL/ABL % by international scale, measured by real-time quantitative polymerase chain reaction (RQ-PCR). BCR-ABL fusion gene is also called the Philadelphia chromosome. The estimated cumulative incidence rates were presented.
Time frame: Baseline up to 12, 24, 48, 72 weeks
Percentage of Patients Achieving Molecular Response 4 (MR4) for Cohorts A, B and C
The rate of molecular response (MR4) by 12, 24, 48 and 72 weeks after the start of first study medication is defined as ≥ 4 log reduction of BCR-ABL (transcript from standardized baseline or ≤ 0.01% BCR-ABL/ABL % by international scale, measured by real-time quantitative polymerase chain reaction (RQ-PCR). BCR-ABL fusion gene is also called the Philadelphia chromosome. The estimated cumulative incidence rates were presented.
Time frame: Baseline up to 12, 24, 48, 72 weeks
Percentage of Patients Achieving Molecular Response 4.5 (MR4.5) for Cohorts A, B and C
The rate of molecular response (MR4.5) by 12, 24, 48 and 72 weeks after the start of first study medication is defined as ≥ 4.5 log reduction of BCR-ABL (transcript from standardized baseline or ≤ 0.0032% BCR-ABL/ABL % by international scale, measured by real-time quantitative polymerase chain reaction (RQ-PCR). BCR-ABL fusion gene is also called the Philadelphia chromosome. The estimated cumulative incidence rates were presented.
Time frame: Baseline up to 12, 24, 48, 72 weeks
Time to Achieve CHR, MR2, MMR, MR4, MR4.5 for Cohorts A, B and C
Time to achieving a response level is defined as the time from the date of the first dose of study medication to the first documented achievement of each defined response level. Time to achieve a specific response level was analyzed using the Kaplan-Meier Product-Limit method. Patients who are known to be without achieving that response level were censored at the last adequate assessment.
Time frame: Baseline up to 72 weeks
Duration of CHR, MR2, MMR, MR4 and MR4.5 for Cohorts A, B and C
Duration of Response (DOR) is the time from the date of the first documented molecular response level to the date of first documented loss of the response level or death due to any cause, whichever occurs first. DOR for each response level was analyzed using the Kaplan-Meier Product-Limit method. Participants continuing without that event were censored at the date of their last adequate response assessment.
Time frame: Baseline up 72 weeks
Progression Free Survival (PFS) for Cohorts A, B and C
Progression Free Survival (PFS) is defined as time from the first dose of study medication to disease progression to accelerated phase/blast crisis (AP/BC) or death due to any cause, whichever occurs first. PFS was analyzed using the Kaplan-Meier Product-Limit method. Subjects who did not progress were censored at the last adequate assessment.
Time frame: Baseline up to 72 weeks
Overall Survival Overall Survival (OS) for Cohorts A, B and C
Overall Survival (OS) is defined as the time from the first dose of study medication to death due to any cause during study. If a patient was not known to have died, then OS was censored at the latest date the patient was known to be alive. OS was analyzed using the Kaplan-Meier Product-Limit method
Time frame: Baseline up to 72 weeks
| Milestone | Cohort A | Cohort B | Cohort C |
|---|---|---|---|
| Started | 26 | 27 | 3 |
| Treated | 25 | 27 | 3 |
| Completed | 12 | 20 | 0 |
| Not completed | 14 | 7 | 3 |
| Withdrew: Physician decision | 9 | 3 | 3 |
| Withdrew: Adverse event | 3 | 1 | 0 |
| Withdrew: Subject decision | 1 | 2 | 0 |
| Withdrew: Progressive disease | 0 | 1 | 0 |
| Withdrew: Enrolled but not treated and discontinued | 1 | 0 | 0 |
| Milestone | Cohort A | Cohort B | Cohort C |
|---|---|---|---|
| Started | 23 | 24 | 3 |
| Completed | 20 | 23 | 3 |
| Not completed | 3 | 1 | 0 |
| Withdrew: Physician decision | 2 | 0 | 0 |
| Withdrew: Subject decision | 1 | 0 | 0 |
| Withdrew: Death | 0 | 1 | 0 |
Adverse events (AEs) and serious adverse events (SAEs) are summarized by cohort. Clinically significant findings for vitals, laboratory values and electrocardiogram (ECG) are reported as adverse events and or serious adverse events as determined by the investigator.
| Participants | Cohort A | Cohort B |
|---|---|---|
| Adverse Events (AEs) | 23 | 26 |
| Serious Adverse Events (SAEs) | 1 | 3 |
| Fatal SAEs | 0 | 1 |
| AEs leading to treatment discontinuation | 2 | 1 |
| AEs leading to dose adjustment/interruption | 7 | 9 |
Adverse events (AEs) and serious adverse events (SAEs) were summarized by cohort. Clinically significant findings for vitals, laboratory values and electrocardiogram (ECG) were reported as adverse events and or serious adverse events as determined by the investigator.
| Participants | Cohort A | Cohort B | Cohort C |
|---|---|---|---|
| Adverse Events (AEs) | 24 | 26 | 3 |
| Serious Adverse Events (SAEs) | 2 | 3 | 1 |
| Fatal SAEs | 0 | 1 | 0 |
| AEs leading to treatment discontinuation | 3 | 1 | 0 |
| AEs leading to dose adjustment/interruption | 7 | 10 | 2 |
Adverse events (AEs) and serious adverse events (SAEs) were summarized by cohort. Clinically significant findings for vitals, laboratory values and electrocardiogram (ECG) were reported as adverse events and or serious adverse events as determined by the investigator.
| Participants | Cohort A | Cohort B | Cohort C |
|---|---|---|---|
| Adverse Events (AEs) | 24 | 26 | 3 |
| Serious Adverse Events (SAEs) | 4 | 4 | 1 |
| Fatal SAEs | 0 | 1 | 0 |
| AEs leading to treatment discontinuation | 3 | 1 | 0 |
| AEs leading to dose adjustment/interruption | 8 | 11 | 2 |
A complete hematologic response (CHR) is defined as all of the following present for ≥ 4 weeks: * White blood cell count (WBC) \<10 x 10\^9/L * Platelet count \<450 x 10\^9/L * Basophils \<5%, * No blasts and promyelocytes in peripheral blood * Myelocytes + metamyelocytes \< 5% in peripheral blood * No evidence of extramedullary disease, including spleen and liver The estimated cumulative incidence rates were presented.
| Percentage of participants | Cohort A | Cohort B | Cohort C |
|---|---|---|---|
| 12 weeks | 76.9 (56.4 to 91.0) | 92.6 (75.7 to 99.1) | 100 (29.2 to 100) |
| 24 weeks | 76.9 (56.4 to 91.0) | 92.6 (75.7 to 99.1) | 100 (29.2 to 100) |
| 48 weeks | 76.9 (56.4 to 91.0) | 92.6 (75.7 to 99.1) | 100 (29.2 to 100) |
| 72 weeks | 76.9 (56.4 to 91.0) | 92.6 (75.7 to 99.1) | 100 (29.2 to 100) |
The rate of major molecular response (MMR) by 12, 24, 48 and 72 weeks after the start of first study medication is defined as ≥ 3 log reduction of BCR-ABL (transcript from standardized baseline or ≤0.1% BCR-ABL/ABL % by international scale, measured by real-time quantitative polymerase chain reaction (RQ-PCR). BCR-ABL fusion gene is also called the Philadelphia chromosome. The estimated cumulative incidence rates were presented.
| Percentage of participants | Cohort A | Cohort B | Cohort C |
|---|---|---|---|
| 12 weeks | 38.5 (20.2 to 59.4) | 44.4 (25.5 to 64.7) | 0 (0.0 to 70.8) |
| 24 weeks | 42.3 (23.4 to 63.1) | 63.0 (42.4 to 80.6) | 0 (0.0 to 70.8) |
| 48 weeks | 46.2 (26.6 to 66.6) | 70.4 (49.8 to 86.3) | 0 (0.0 to 70.8) |
| 72 weeks | 50.0 (29.9 to 70.1) | 70.4 (49.8 to 86.3) | 0 (0.0 to 70.8) |
The rate of molecular response (MR2) by 12, 24, 48 and 72 weeks after the start of first study medication is defined as ≥ 2 log reduction of BCR-ABL (transcript from standardized baseline or ≤ 1% BCR-ABL/ABL % by international scale, measured by real-time quantitative polymerase chain reaction (RQ-PCR). BCR-ABL fusion gene is also called the Philadelphia chromosome. The estimated cumulative incidence rates were presented.
| Percentage of participants | Cohort A | Cohort B | Cohort C |
|---|---|---|---|
| 12 weeks | 53.8 (33.4 to 73.4) | 70.4 (49.8 to 86.3) | 0 (0.0 to 70.8) |
| 24 weeks | 57.7 (36.9 to 76.7) | 85.2 (66.3 to 95.8) | 0 (0.0 to 70.8) |
| 48 weeks | 61.5 (40.6 to 79.8) | 85.2 (66.3 to 95.8) | 0 (0.0 to 70.8) |
| 72 weeks | 61.5 (10.6 to 79.8) | 85.2 (66.3 to 95.8) | 0 (0.0 to 70.8) |
The rate of molecular response (MR4) by 12, 24, 48 and 72 weeks after the start of first study medication is defined as ≥ 4 log reduction of BCR-ABL (transcript from standardized baseline or ≤ 0.01% BCR-ABL/ABL % by international scale, measured by real-time quantitative polymerase chain reaction (RQ-PCR). BCR-ABL fusion gene is also called the Philadelphia chromosome. The estimated cumulative incidence rates were presented.
| Percentage of participants | Cohort A | Cohort B | Cohort C |
|---|---|---|---|
| 12 weeks | 30.8 (14.3 to 51.8) | 18.5 (6.3 to 38.1) | 0 (0.0 to 70.8) |
| 24 weeks | 30.8 (14.3 to 51.8) | 29.6 (13.8 to 50.2) | 0 (0.0 to 70.8) |
| 48 weeks | 38.5 (20.2 to 59.4) | 44.4 (25.5 to 64.7) | 0 (0.0 to 70.8) |
| 72 weeks | 38.5 (20.2 to 59.4) | 48.1 (28.7 to 68.1) | 0 (0.0 to 70.8) |
The rate of molecular response (MR4.5) by 12, 24, 48 and 72 weeks after the start of first study medication is defined as ≥ 4.5 log reduction of BCR-ABL (transcript from standardized baseline or ≤ 0.0032% BCR-ABL/ABL % by international scale, measured by real-time quantitative polymerase chain reaction (RQ-PCR). BCR-ABL fusion gene is also called the Philadelphia chromosome. The estimated cumulative incidence rates were presented.
| Percentage of participants | Cohort A | Cohort B | Cohort C |
|---|---|---|---|
| 12 weeks | 23.1 (9.0 to 43.7) | 11.1 (2.4 to 29.2) | 0 (0.0 to 70.8) |
| 24 weeks | 26.9 (11.6 to 47.8) | 18.5 (6.3 to 38.1) | 0 (0.0 to 70.8) |
| 48 weeks | 30.8 (14.3 to 51.8) | 25.9 (11.1 to 46.3) | 0 (0.0 to 70.8) |
| 72 weeks | 30.8 (14.3 to 51.8) | 29.6 (13.8 to 50.2) | 0 (0.0 to 70.8) |
Time to achieving a response level is defined as the time from the date of the first dose of study medication to the first documented achievement of each defined response level. Time to achieve a specific response level was analyzed using the Kaplan-Meier Product-Limit method. Patients who are known to be without achieving that response level were censored at the last adequate assessment.
| weeks | Cohort A | Cohort B | Cohort C |
|---|---|---|---|
| CHR | 11.1 (11.1 to 12.00) | 11.9 (11.1 to 12.1) | 11.1 (10.9 to NA) |
| MMR | 24.0 (4.1 to NA) | 22.9 (11.1 to 28.3) | NA (NA to NA) |
| MR2 | 8.3 (4.0 to 47.0) | 4.3 (3.9 to 11.6) | NA (NA to NA) |
| MR4 | 36.1 (11.1 to NA) | 58.6 (23.1 to NA) | NA (NA to NA) |
| MR4.5 | NA (23.1 to NA) | NA (48.1 to NA) | NA (NA to NA) |
Duration of Response (DOR) is the time from the date of the first documented molecular response level to the date of first documented loss of the response level or death due to any cause, whichever occurs first. DOR for each response level was analyzed using the Kaplan-Meier Product-Limit method. Participants continuing without that event were censored at the date of their last adequate response assessment.
| weeks | Cohort A | Cohort B | Cohort C |
|---|---|---|---|
| CHR | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
| MMR | NA (NA to NA) | NA (NA to NA) | — |
| MR2 | NA (NA to NA) | NA (NA to NA) | — |
| MR 4 | NA (NA to NA) | NA (2.9 to NA) | — |
| MR 4.5 | NA (NA to NA) | NA (NA to NA) | — |
Progression Free Survival (PFS) is defined as time from the first dose of study medication to disease progression to accelerated phase/blast crisis (AP/BC) or death due to any cause, whichever occurs first. PFS was analyzed using the Kaplan-Meier Product-Limit method. Subjects who did not progress were censored at the last adequate assessment.
| weeks | Cohort A | Cohort B | Cohort C |
|---|---|---|---|
| Progression Free Survival (PFS) for Cohorts A, B and C | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
Overall Survival (OS) is defined as the time from the first dose of study medication to death due to any cause during study. If a patient was not known to have died, then OS was censored at the latest date the patient was known to be alive. OS was analyzed using the Kaplan-Meier Product-Limit method
| weeks | Cohort A | Cohort B | Cohort C |
|---|---|---|---|
| Overall Survival Overall Survival (OS) for Cohorts A, B and C | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
Collected over From Baseline to 30 days after last treatment (up to a maximum of approximately 85 weeks).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort A | 0/25 (0%) | 4/25 (16%) | 24/25 (96%) |
| Cohort B | 2/27 (7.4%) | 4/27 (14.8%) | 26/27 (96.3%) |
| Cohort C | 0/3 (0%) | 1/3 (33.3%) | 3/3 (100%) |
| Event | Cohort A | Cohort B | Cohort C |
|---|---|---|---|
| MalaiseGeneral disorders | 0/25 | 0/27 | 1/3 |
| COVID-19 pneumoniaInfections and infestations | 1/25 | 0/27 | 0/3 |
| Pelvic infectionInfections and infestations | 1/25 | 0/27 | 0/3 |
| Meniscus injuryInjury, poisoning and procedural complications | 1/25 | 0/27 | 0/3 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/25 | 0/27 | 0/3 |
| Neuroendocrine tumourNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/25 | 0/27 | 0/3 |
| Brain stem infarctionNervous system disorders | 1/25 | 0/27 | 0/3 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 1/25 | 0/27 | 0/3 |
| Acute coronary syndromeCardiac disorders | 0/25 | 1/27 | 0/3 |
| Myocardial infarctionCardiac disorders | 0/25 | 1/27 | 0/3 |
| Event | Cohort A | Cohort B | Cohort C |
|---|---|---|---|
| NauseaGastrointestinal disorders | 3/25 | 8/27 | 2/3 |
| FatigueGeneral disorders | 10/25 | 9/27 | 1/3 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 6/25 | 10/27 | 1/3 |
| HeadacheNervous system disorders | 9/25 | 7/27 | 0/3 |
| AnaemiaBlood and lymphatic system disorders | 0/25 | 2/27 | 1/3 |
| ThrombocytopeniaBlood and lymphatic system disorders | 2/25 | 2/27 | 1/3 |
| Abdominal distensionGastrointestinal disorders | 1/25 | 0/27 | 1/3 |
| VomitingGastrointestinal disorders | 3/25 | 5/27 | 1/3 |
| Oedema peripheralGeneral disorders | 2/25 | 3/27 | 1/3 |
| Viral diarrhoeaInfections and infestations | 0/25 | 0/27 | 1/3 |
| Age, Categorical(Participants) | Cohort A | Cohort B | Cohort C | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 17 | 19 | 3 | 39 |
| >=65 years | 9 | 8 | 0 | 17 |
| Sex: Female, Male(Participants) | Cohort A | Cohort B | Cohort C | Total |
|---|---|---|---|---|
| Female | 16 | 14 | 0 | 30 |
| Male | 10 | 13 | 3 | 26 |
| Race (NIH/OMB)(Participants) | Cohort A | Cohort B | Cohort C | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 2 | 0 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 4 | 2 | 1 | 7 |
| White | 21 | 22 | 1 | 44 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 1 | 1 | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on https://www.clinicalstudydatarequest.com/
Ran from May 2021 to primary completion in Jun 2023, 24 months.
Results were first posted in Jul 2024, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Asciminib
Leukemia, Myeloid, Chronic-Phase →